PharmaCyte Biotech, Inc.
PMCB evidence brief
What we can confirm
- Market Cap:
- $4.5M
What it means
What to watch
Prepared research question
What matters most for PMCB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMCB
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cell encapsulation therapies for locally advanced pancreatic cancer (LAPC), currently working to lift an FDA clinical hold on its IND to commence a planned clinical trial.
Key risk: FDA clinical hold unresolved
Market Cap
$4.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cell encapsulation therapies for locally advanced pancreatic cancer (LAPC), currently working to lift an FDA clinical hold on its IND to commence a planned clinical trial.
- PharmaCyte is developing a cell encapsulation therapy (CypCaps™) for locally advanced pancreatic cancer (LAPC) [sec_mda · as of 2026-03-17].
- The company's IND for a planned LAPC clinical trial is under an FDA clinical hold, which the company is actively working to resolve [sec_mda · as of 2026-07-29].
- As of January 31, 2026, the company had approximately $20.2 million in cash and cash equivalents, with about $19 million as of the filing of its quarterly report, expected to fund operations for at least the next twelve months [sec_mda · as of 2026-03-17].
- In August 2025, the company raised $7 million in gross proceeds through a private placement of Series C convertible preferred stock and warrants [sec_mda · as of 2026-03-17].
- The company has authorized share repurchase programs, but did not repurchase any shares during the year ended April 30, 2026 [sec_mda · as of 2026-07-29].
What works
- The company has a cash runway of at least twelve months from its latest quarterly report, providing a buffer to advance regulatory and preclinical work [sec_mda · as of 2026-03-17].
- Management is actively engaged with SG Austria to prepare syringes filled with the latest generation of CypCaps™ for preclinical studies and the planned clinical trial [sec_mda · as of 2026-03-17].
- The clinical hold was placed due to non-clinical issues, not deficiencies in the proposed clinical trial itself, suggesting the path to resolution may be focused on manufacturing and preclinical data [sec_mda · as of 2025-03-17].
What to weigh
- The company's IND remains under clinical hold, and there is no guarantee that the FDA will lift it, which delays the start of the planned LAPC trial [sec_mda · as of 2026-07-29].
- The company faces numerous tasks required by the FDA to lift the clinical hold, and success depends on completing all of them, which introduces execution risk [sec_mda · as of 2026-07-29].
- The company has no approved products and has not yet commenced its planned clinical trial, meaning it is still in a pre-revenue stage with no near-term commercial prospects [sec_mda · as of 2026-07-29].
- The company's ability to progress is tied to third-party contracts and related-party transactions, which could affect timeliness and financial position [sec_mda · as of 2026-07-29].
From the filings
Quoted directly from source documents.
The company is working to lift an FDA clinical hold on its IND for a LAPC trial.
“complete all of the tasks the FDA requires of us in order to have the clinical hold lifted; and (viii) obtain approval from the FDA to lift the clinical hold on our IND that we may commence our planned clinical trial in LAPC.”
SEC MD&A · July 29, 2026
The company had approximately $20.2 million in cash as of January 31, 2026.
“As of January 31, 2026, we had approximately $20.2 million in cash and cash equivalents as compared to approximately $15.2 million at April 30, 2025.”
SEC MD&A · March 17, 2026
The clinical hold was due to non-clinical issues, not trial design deficiencies.
“The clinical hold did not reflect any deficiencies of the clinical trial proposed. We seek to resolve these non-clinical issues to enable FDA review of a new clinical protocol that reflects the standard of care for LAPC.”
SEC MD&A · March 17, 2025
The company raised $7 million in August 2025 via a private placement.
“In August 2025, we entered into a securities purchase agreement pursuant to which we agreed to sell to investors in a private placement an aggregate of 7,000 shares of our newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to 7 million shares of our Common Stock, resulting in aggregate gross proceeds of $7 million.”
SEC MD&A · March 17, 2026
Risks & what to watch (4)›
Key risks
- FDA clinical hold unresolved — The IND for the LAPC trial remains under clinical hold; failure to lift it would delay or prevent the trial [sec_mda · as of 2026-07-29].
- Execution risk on regulatory tasks — Numerous FDA-required tasks must be completed successfully, with no guarantee of timely completion [sec_mda · as of 2026-07-29].
- Dependence on third parties — Progress relies on contracts with SG Austria and other parties, which may affect timeliness and financial results [sec_mda · as of 2026-07-29].
- Pre-revenue stage with no approved products — The company has no approved products and has not commenced its planned clinical trial, with no near-term revenue [sec_mda · as of 2026-07-29].
What to watch
- FDA decision on lifting the clinical hold for the LAPC IND [sec_mda · as of 2026-07-29].
- Completion of syringe preparation with the latest CypCaps™ generation for preclinical studies [sec_mda · as of 2026-03-17].
- Cash burn rate and any additional financing activities, given the $19 million cash position as of the latest filing [sec_mda · as of 2026-03-17].
- Progress on non-clinical tasks required by the FDA, including manufacturing and preclinical data submissions [sec_mda · as of 2026-07-29].
Sources: SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run PharmaCyte Biotech, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PharmaCyte Biotech, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$602K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 359,547 | $239K |
| geode capital management, llc | 195,660 | $130K |
| renaissance technologies llc | 56,500 | $38K |
| xtx topco ltd | 52,362 | $35K |
| vanguard capital management llc | 51,467 | $34K |
| northern trust corp | 35,601 | $24K |
| schonfeld strategic advisors llc | 27,009 | $18K |
| vanguard fiduciary trust co | 23,452 | $16K |
| equitec proprietary markets, llc | 22,227 | $15K |
| simplex trading, llc | 19,940 | $13K |
Showing top 10 of 32 institutional holders of PharmaCyte Biotech, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.0%
- Days to cover
- 0.6
- Shares short
- 97,390
- Daily short volume (Oct 12, 2026)
- 64.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMCB short interestGovernance
Frequently asked questions
What is the AI investment thesis for PharmaCyte Biotech, Inc.?
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cell encapsulation therapies for locally advanced pancreatic cancer (LAPC), currently working to lift an FDA clinical hold on its IND to commence a planned clinical trial.
Who is the CEO of PharmaCyte Biotech, Inc.?
Mr. Joshua N. Silverman is the chief executive officer of PharmaCyte Biotech, Inc. (PMCB).
Where is PharmaCyte Biotech, Inc. headquartered?
PharmaCyte Biotech, Inc. (PMCB) is headquartered in Las Vegas, NV, United States.
What therapeutic areas does PharmaCyte Biotech, Inc. focus on?
PharmaCyte Biotech, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.